| Riley Clark, MD | |
|
5225 23rd Ave S, Fargo, ND 58104-7927 | |
| (701) 417-2000 | |
| Not Available |
| Full Name | Riley Clark |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 8 Years |
| Location | 5225 23rd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114370814 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 15687 (North Dakota) | Primary |
| 207R00000X | Internal Medicine | RL14170 (North Dakota) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.
The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.
Yesterday the U.S. Food and Drug Administration gave its approval to Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C infection. These patients are infected with the Hepatitis C virus (HCV) of genotypes 1-6 and are those that have not developed liver cirrhosis or those who have developed mild cirrhosis. The approval for Mavyret was given to AbbVie Inc.
Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.
› Verified 7 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.
The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.
Yesterday the U.S. Food and Drug Administration gave its approval to Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C infection. These patients are infected with the Hepatitis C virus (HCV) of genotypes 1-6 and are those that have not developed liver cirrhosis or those who have developed mild cirrhosis. The approval for Mavyret was given to AbbVie Inc.
Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.
› Verified 7 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.
The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.
Yesterday the U.S. Food and Drug Administration gave its approval to Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C infection. These patients are infected with the Hepatitis C virus (HCV) of genotypes 1-6 and are those that have not developed liver cirrhosis or those who have developed mild cirrhosis. The approval for Mavyret was given to AbbVie Inc.
Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Riley Clark, MD Po Box 5074, Sioux Falls, SD 57117-5074 Ph: () - | Riley Clark, MD 5225 23rd Ave S, Fargo, ND 58104-7927 Ph: (701) 417-2000 |
News Archive
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.
The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.
Yesterday the U.S. Food and Drug Administration gave its approval to Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C infection. These patients are infected with the Hepatitis C virus (HCV) of genotypes 1-6 and are those that have not developed liver cirrhosis or those who have developed mild cirrhosis. The approval for Mavyret was given to AbbVie Inc.
Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.
› Verified 7 days ago
Malik Muhammad Anwar Ul Haq, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 | |
Christina Harmon, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 | |
Irina Hillman, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-417-2575 Fax: 701-417-2535 | |
Hannah Margaret Schradick, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-234-5933 | |
James D Fowler, PA Hospitalist Medicare: Medicare Enrolled Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-417-2575 | |
Weimin Hao, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 737 Broadway, Fargo, ND 58122 Phone: 701-234-2731 Fax: 701-234-2158 |